Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate (Stribild) is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed.
• The total number of studies reviewed was 2 from systematic reviews/meta-analyses.
• Stribild demonstrated high rates of HIV and HBV viral suppression (>94% for HIV RNA), with improvements noted in renal function and bone mineral density among an Asian population coinfected with HIV/HBV.
• Compared to long-acting cabotegravir (CAB-LA) plus rilpivirine (RPV-LA), which showed superior efficacy in preventing HIV infection but had common mild to moderate injection site reactions, Stribild maintained similar levels of virological suppression without such localized adverse effects.
• Subgroup considerations revealed that more than 85% preferred long-term injectable formulations like CAB-LA+RPV-LA over daily oral regimens; however, specific benefits were observed with Stribild regarding renal function improvement and bone health within its evaluated populations.
• While both treatments offer effective viral suppression options, patient preferences towards administration routes may influence adherence outcomes significantly.